Form 4: Vir Bio Director Sells Shares Under 10b5-1 Plan

Vicki L. Sato, a Director at Vir Biotechnology, Inc., sold 22,000 shares of common stock for a weighted average price of $5.6385 per share pursuant to a pre-arranged trading plan.

Summary

• Vicki L. Sato, a Director of Vir Biotechnology, Inc. (VIR), reported the sale of 22,000 shares of common stock.
• The transaction occurred on November 3, 2025.
• The shares were sold at a weighted average price of $5.6385, with individual sales ranging from $5.51 to $5.90.
• The sale was executed under a Rule 10b5-1 trading plan adopted by Ms. Sato on March 27, 2025.
• Following this transaction, Ms. Sato beneficially owns 1,210,391 shares of common stock directly.

Sentiment

Score: 5

Explanation: The sale of shares by a director is generally a neutral to slightly negative signal. However, the fact that it was executed under a pre-arranged Rule 10b5-1 trading plan mitigates concerns that the sale is based on new, negative non-public information, leading to a neutral sentiment score.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on new, non-public information.

Negatives

• A director selling shares can sometimes be interpreted by the market as a lack of confidence in the company's near-term prospects.

Risks

• Potential negative market sentiment if investors misinterpret the sale as a signal of declining company performance, despite the 10b5-1 plan.

Future Outlook

NA

Industry Context

This Form 4 filing reports a routine insider transaction for a biotechnology company. Insider sales, even under 10b5-1 plans, are common in the industry as executives manage personal finances and diversify portfolios. The specific implications for Vir Biotechnology would depend on the broader context of its drug development pipeline and market performance, which are not detailed in this filing.

Stakeholder Impact

• Shareholders may perceive the director's sale as a slight negative, potentially impacting investor confidence, although the 10b5-1 plan reduces this concern.

Key Dates

Recommendation

The sale of shares by Director Vicki L. Sato is a pre-planned transaction under a Rule 10b5-1 plan, adopted several months prior. This suggests the sale is for personal financial management rather than a reaction to new, adverse company developments. While insider selling can sometimes create negative sentiment, the pre-scheduled nature of this transaction limits its interpretative impact on the company's fundamental outlook. Therefore, a 'hold' recommendation is appropriate, as this specific filing does not provide new information warranting a change in investment thesis.

Keywords

Vir Biotechnology, VIR, Form 4, Insider Trading, Stock Sale, Director, Vicki L. Sato, 10b5-1 Plan, Biotechnology